Anthrax Vaccine Market Insights 2025-2034: Growth Forecast and Strategic Priorities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anthrax Vaccine Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the size of the anthrax vaccine market has experienced significant growth. It is anticipated to escalate from $11.27 billion in 2024 to $11.88 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to the growth in the historic period include concerns about biological warfare, military demand, incidents of anthrax outbreaks, public health readiness, and biodefense initiatives.

Anthrax Vaccine Market Size Forecast: What's the Projected Valuation by 2029?
The market size for the anthrax vaccine is projected to witness robust growth in the forthcoming years, with an estimated value of $14.5 billion anticipated by 2029. This suggests a compound annual growth rate (CAGR) of 5.1%. The projected growth within this period can be accredited to worldwide security concerns, the emergence of new threats, the initiatives taken by governments for purchase, and preparedness for pandemics. Key trends anticipated during this projected period encompass advancements in technology, improved access in developing nations, emphasis on next-generation vaccines, augmented government reserves, as well as collaborative research undertakings.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

What Are the Drivers Transforming the Anthrax Vaccine Market?
The growth of the anthrax vaccine market is anticipated to be driven by the increasing occurrence of infectious diseases. These diseases get transmitted either directly or indirectly from one person to another, and are caused by pathogenic organisms such as viruses, bacteria, parasites, or fungus. Depending on various factors like the type of pathogen and the immune response of the individual, these diseases can produce symptoms that range from mild to severe, and in some cases, even lethal. The rise in infectious diseases can be attributed to several factors including demographic shifts, urbanization, changes in land use and environment, and alterations in human behavior. The anthrax vaccine is primarily used for anthrax protection, however, its potential use in combating other infectious diseases is currently being investigated, focusing on its immunogenic features and adaptability. For instance, the Council on Foreign Relations, a U.S. nonprofit organization, reported in February 2023 that approximately 75% of newly identified or emerging infectious diseases (EIDs) and 60% of acknowledged infectious diseases are of zoonotic origin. Moreover, around 2.7 million deaths and 2.5 billion incidences of disease annually are caused by zoonoses globally. Thus, due to the increasing disease prevalence, the anthrax vaccine market is poised for growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What Long-Term Trends Will Define the Future of the Anthrax Vaccine Market?
Leading firms engaged in the anthrax vaccine marketplace have been focusing their efforts on the creation of novel products and obtaining FDA validations for their immunizations, ensuring safety, efficiency, and accessibility for those at risk of anthrax exposure. This validation by the FDA assures that the vaccine has undergone rigorous clinical trial testing and has been deemed safe for the public, mitigating potential negative side effects. The relevance of this was demonstrated when Emergent BioSolutions Inc., a biopharmaceutical company originating from the U.S., gained approval in July 2023 for CYFENDUS, previously named AV7909. This authorization by the U.S. Food and Drug Administration (FDA) was informed by data from a phase 2 trial, which assessed whether Cyfendus interfered with antibacterial medicine, and a phase 3 study, which compared the vaccine's immunogenicity and safety with BioThrax, the predecessor anthrax vaccine. Importantly, to combat reactogenicity issues and improve the global efficiency of anthrax vaccines, it's essential to innovate safer and more effective adjuvants.

Which Segments in the Anthrax Vaccine Market Offer the Most Profit Potential?
The anthrax vaccine market covered in this report is segmented -

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

Which Firms Dominate the Anthrax Vaccine Market by Market Share and Revenue in 2025?
Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

Which Regions Offer the Highest Growth Potential in the Anthrax Vaccine Market?
North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.